1126 related articles for article (PubMed ID: 19479852)
21. Protein interaction for an interferon-inducible systemic lupus associated gene, IFIT1.
Ye S; Pang H; Gu YY; Hua J; Chen XG; Bao CD; Wang Y; Zhang W; Qian J; Tsao BP; Hahn BH; Chen SL; Rao ZH; Shen N
Rheumatology (Oxford); 2003 Oct; 42(10):1155-63. PubMed ID: 12777642
[TBL] [Abstract][Full Text] [Related]
22. Fatigue in patients with systemic lupus erythematosus: lack of associations to serum cytokines, antiphospholipid antibodies, or other disease characteristics.
Omdal R; Mellgren SI; Koldingsnes W; Jacobsen EA; Husby G
J Rheumatol; 2002 Mar; 29(3):482-6. PubMed ID: 11908560
[TBL] [Abstract][Full Text] [Related]
23. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
Stohl W; Metyas S; Tan SM; Cheema GS; Oamar B; Xu D; Roschke V; Wu Y; Baker KP; Hilbert DM
Arthritis Rheum; 2003 Dec; 48(12):3475-86. PubMed ID: 14673998
[TBL] [Abstract][Full Text] [Related]
24. Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells.
Karonitsch T; Feierl E; Steiner CW; Dalwigk K; Korb A; Binder N; Rapp A; Steiner G; Scheinecker C; Smolen J; Aringer M
Arthritis Rheum; 2009 May; 60(5):1463-71. PubMed ID: 19404947
[TBL] [Abstract][Full Text] [Related]
25. The effect of immunosuppressive therapy on the messenger RNA expression of target genes in the urinary sediment of patients with active lupus nephritis.
Chan RW; Lai FM; Li EK; Tam LS; Chow KM; Li PK; Szeto CC
Nephrol Dial Transplant; 2006 Jun; 21(6):1534-40. PubMed ID: 16449281
[TBL] [Abstract][Full Text] [Related]
26. Genetic susceptibility to polyI:C-induced IFNalpha/beta-dependent accelerated disease in lupus-prone mice.
Jørgensen TN; Thurman J; Izui S; Falta MT; Metzger TE; Flannery SA; Kappler J; Marrack P; Kotzin BL
Genes Immun; 2006 Oct; 7(7):555-67. PubMed ID: 16900204
[TBL] [Abstract][Full Text] [Related]
27. Characterization of 5C11-positive activated interferon-producing cells in patients with systemic lupus erythematosus.
Ohshima M; Kanda H; Kubo K; Yonezumi-Hayashi A; Tateishi S; Yamamoto K
Lupus; 2013 Jan; 22(1):44-51. PubMed ID: 23087259
[TBL] [Abstract][Full Text] [Related]
28. Lupus-like disease and high interferon levels corresponding to trisomy of the type I interferon cluster on chromosome 9p.
Zhuang H; Kosboth M; Lee P; Rice A; Driscoll DJ; Zori R; Narain S; Lyons R; Satoh M; Sobel E; Reeves WH
Arthritis Rheum; 2006 May; 54(5):1573-9. PubMed ID: 16645992
[TBL] [Abstract][Full Text] [Related]
29. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus.
Tew GW; Rabbee N; Wolslegel K; Hsieh HJ; Monroe JG; Behrens TW; Brunetta PG; Keir ME
Lupus; 2010 Feb; 19(2):146-57. PubMed ID: 19946034
[TBL] [Abstract][Full Text] [Related]
30. Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus.
Feng X; Wu H; Grossman JM; Hanvivadhanakul P; FitzGerald JD; Park GS; Dong X; Chen W; Kim MH; Weng HH; Furst DE; Gorn A; McMahon M; Taylor M; Brahn E; Hahn BH; Tsao BP
Arthritis Rheum; 2006 Sep; 54(9):2951-62. PubMed ID: 16947629
[TBL] [Abstract][Full Text] [Related]
31. Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model.
Plater-Zyberk C; Joosten LA; Helsen MM; Koenders MI; Baeuerle PA; van den Berg WB
Ann Rheum Dis; 2009 May; 68(5):721-8. PubMed ID: 18495731
[TBL] [Abstract][Full Text] [Related]
32. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjögren's syndrome autoantigen-associated RNA.
Lövgren T; Eloranta ML; Kastner B; Wahren-Herlenius M; Alm GV; Rönnblom L
Arthritis Rheum; 2006 Jun; 54(6):1917-27. PubMed ID: 16729300
[TBL] [Abstract][Full Text] [Related]
33. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus.
Vallin H; Perers A; Alm GV; Rönnblom L
J Immunol; 1999 Dec; 163(11):6306-13. PubMed ID: 10570325
[TBL] [Abstract][Full Text] [Related]
34. Expression and function of inducible co-stimulator in patients with systemic lupus erythematosus: possible involvement in excessive interferon-gamma and anti-double-stranded DNA antibody production.
Kawamoto M; Harigai M; Hara M; Kawaguchi Y; Tezuka K; Tanaka M; Sugiura T; Katsumata Y; Fukasawa C; Ichida H; Higami S; Kamatani N
Arthritis Res Ther; 2006; 8(3):R62. PubMed ID: 16563187
[TBL] [Abstract][Full Text] [Related]
35. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.
Wang H; Li T; Chen S; Gu Y; Ye S
Arthritis Rheumatol; 2015 Dec; 67(12):3190-200. PubMed ID: 26245802
[TBL] [Abstract][Full Text] [Related]
36. Differential effect of IL10 and TNF{alpha} genotypes on determining susceptibility to discoid and systemic lupus erythematosus.
Suárez A; López P; Mozo L; Gutiérrez C
Ann Rheum Dis; 2005 Nov; 64(11):1605-10. PubMed ID: 15800006
[TBL] [Abstract][Full Text] [Related]
37. Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus.
Hellmich B; Csernok E; Schatz H; Gross WL; Schnabel A
Arthritis Rheum; 2002 Sep; 46(9):2384-91. PubMed ID: 12355486
[TBL] [Abstract][Full Text] [Related]
38. The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus.
Toubi E; Kessel A; Rosner I; Rozenbaum M; Paran D; Shoenfeld Y
Scand J Immunol; 2006 Apr; 63(4):299-303. PubMed ID: 16623930
[TBL] [Abstract][Full Text] [Related]
39. Anti-ribosomal P protein antibody in human systemic lupus erythematosus up-regulates the expression of proinflammatory cytokines by human peripheral blood monocytes.
Nagai T; Arinuma Y; Yanagida T; Yamamoto K; Hirohata S
Arthritis Rheum; 2005 Mar; 52(3):847-55. PubMed ID: 15751081
[TBL] [Abstract][Full Text] [Related]
40. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus.
Llorente L; Richaud-Patin Y; García-Padilla C; Claret E; Jakez-Ocampo J; Cardiel MH; Alcocer-Varela J; Grangeot-Keros L; Alarcón-Segovia D; Wijdenes J; Galanaud P; Emilie D
Arthritis Rheum; 2000 Aug; 43(8):1790-800. PubMed ID: 10943869
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
